A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
This study has been completed.
Information provided by (Responsible Party):
First received: July 26, 2007
Last updated: June 10, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2011|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||March 2, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Besse B, Planchard D, Veillard AS, Taillade L, Khayat D, Ducourtieux M, Pignon JP, Lumbroso J, Lafontaine C, Mathiot C, Soria JC. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Apr;76(1):78-83. doi: 10.1016/j.lungcan.2011.09.006. Epub 2011 Dec 18.